Michael Verni
3 Papers
6 Citations
Michael Verni is an academic researcher. The author has contributed to research in topics: Renal pelvis & Bladder cancer. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial
Nir Kleinmann,Surena F. Matin,Phillip M. Pierorazio,John L. Gore,Ahmad Shabsigh,Brian Hu,Karim Chamie,Guilherme Godoy,Scott G. Hubosky,Marcelino E. Rivera,Michael A. O’Donnell,Marcus L. Quek,Jay D. Raman,John J. Knoedler,Douglas S. Scherr,Joshua Stern,Christopher J. Weight,Alon Z. Weizer,Michael Woods,Hristos Z. Kaimakliotis,Angela B. Smith,Jennifer M Linehan,Jonathan A. Coleman,Mitchell R. Humphreys,Raymond Pak,David A. Lifshitz,Michael Verni,Mehrad Adibi,Mahul B. Amin,Elyse Seltzer,Ifat Klein,Marina Konorty,Dalit Strauss-Ayali,Gil Hakim,Mark Schoenberg,Seth P. Lerner +35 more
TL;DR: Primary chemoablation of low-grade upper tract urothelial cancer with intracavitary UGN-101 results in clinically significant disease eradication and might offer a kidney-sparing treatment alternative for these patients.
125
Lba-16 nephron-sparing management of low grade (lg) utuc with ugn-101 (mitomycin gel) for instillation: the olympus trial experience
Nir Kleinmann,Surena F. Matin,Philip Pierorazio,John C. Gore,Ahmad Shabsigh,Brian Hu,Karim Chamie,Guy Godoy,Scott G. Hubosky,Marcelino Rivera,Michael A. O’Donnell,Marcus L. Quek,Jay D. Raman,Douglas S. Scherr,Joshua M. Stern,Christopher J. Weight,Alon Z. Weizer,Michael Woods,Hristos Z. Kaimakliotis,Angela Smith VChapel,Jennifer Linehan,Jonathan A. Coleman,Mitchell R. Humphreys,Raymond Pak,David A. Lifshitz,Michael Verni,Elyse Seltzer,Ifat Klein,Mark P. Schoenberg,Seth P. Lerner +29 more
TL;DR: Data from the Olympus Trial suggest that a minimally invasive chemoablation approach utilizing UGN-101 in this population results in a high rate of initial disease eradication obviating the need for kidney removal in nearly half of treated individuals.
6
Lba02-03 can turbt be avoided? primary chemoablation with a reverse thermal gel containing mitomycin (ugn-102) in patients with low grade intermediate risk non-muscle invasive bladder cancer
William J.S. Huang,K. Kent Chevli,Andrew Trainer,Angela R. Smith,Daniel Saltzstein,Yaron Ehrlich,Boris Friedman,Richard D’Anna,David L. Morris,Brian Hu,Mark D. Tyson,Alexander Sankin,Max Kates,Jennifer Linehan,Douglas S. Scherr,Steven Kester,Michael Verni,Karim Chamie,Lawrence Karsch,Arnold Cinman,Elyse Seltzer,Nimrod Gabai,Robert Kirshoff,Mark P. Schoenberg,Jay D. Raman,Neal D. Shore +25 more
TL;DR: Low grade, intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC) is notable for a high rate of disease recurrence yet low risk of disease progression.
3